Notch1 in primary effusion lymphoma: a clinicopathological study

Wang, Huan You; Fuda, Franklin; Chen, Weina; Karandikar, Nitin J.

doi:10.1038/modpathol.2010.67

Cited by 26 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PT-PEL occurrence was reported in 7 renal and in 3 cardiac transplant recipients, in concomitance with PT-KS in 2 cases, and leading to patient's exitus in most cases, particularly after heart transplantation. [45][46][47][48][49][50][51][52] Furthermore, we have recently observed 2 patients who rapidly died with pleural and peritoneal effusions early after liver transplant, and the autopsy revealed a PEL diagnosis in both cases (M.L., unpublished data, December 2005; M.L. and T. Lazzarotto, unpublished data, June 2011).…”

Section: Posttransplantation Ks Pel and MCDmentioning

confidence: 99%

How I treat HHV8/KSHV-related diseases in posttransplant patients

Riva¹,

Luppi²,

Barozzi³

et al. 2012

Blood

View full text Add to dashboard Cite

Posttransplantation human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) primary infection and/or reactivations are associated with uncommon and sometimes fatal, neoplastic, and nonneoplastic diseases. HHV8-related clinical manifestations notably range from Kaposi sarcoma (KS) to either primary effusion lymphoma or multicentric Castleman disease B-cell malignancies, and from polyclonal HHV8-positive plasmacytic lymphoproliferative disorders to bone marrow failure and peripheral cytopenias, associated or not with hemophagocytic syndromes, and to acute hepatitis syndromes. We reviewed the patient series reported in the literature and summarized clinical management aspects, in terms of diagnosis, follow-up, and treatment. We described typical clinical presentations and histopathologic diagnostic features of these diseases, and we discussed the role of HHV8-specific serologic, molecular, and immunologic assays, particularly focusing on recent data from HHV8-specific T-cell monitoring in posttransplantation KS patients. We finally discussed actual therapeutic options, namely, the reduction or discontinuation of immunosuppressive therapy or the switch from calcineurin inhibitors to mTOR inhibitors, as alternatives to antineoplastic chemotherapy, along with the use of antiherpesvirus agents as prophylactic or therapeutic measures, and treatment with rituximab in posttransplantation multicentric Castleman disease patients and non-neoplastic HHV8-associated syndromes. IntroductionHerpesvirus-associated hematologic diseases often represent primary clinical challenges during the multidisciplinary follow-up of posttransplant patients, either with hematopoietic stem cell transplant (HSCT) or with solid organ transplant (SOT). In immunosuppressed organ recipients, latent human ␥-herpesvirus, namely, EBV and human herpesvirus-8 (HHV8)/Kaposi sarcoma herpesvirus (KSHV) are typically responsible for several virus-driven neoplastic proliferations, as well as they may sometimes cause uncommon, but equally life-threatening, non-neoplastic infectious complications. During the past decade, large amounts of experimental evidence have come out on these topics, and some of them have yet begun to influence the clinical behavior, in terms of diagnosis and treatment. Chiefly, EBV-related complications have been extensively studied and discussed, so that now physicians can rely on accurate and updated clinical recommendations, in particular dealing with early diagnosis, monitoring and treatment of EBV ϩ posttransplantation lymphoproliferative diseases (PTLDs). 1 With regards to HHV8, practical management of the virus-associated neoplastic lymphoproliferations has deeply been revised in HIVpositive subjects, 2,3 whereas in SOT and HSCT settings, the diagnostic and therapeutic issues about the various HHV8-driven manifestations (either neoplastic or non-neoplastic) are only occasionally reported in the literature, but most of these diseases revealed to be rapidly lethal if not timely recognized and adequately treated. Indeed, posttra...

show abstract

Section: Posttransplantation Ks Pel and MCDmentioning

confidence: 99%

How I treat HHV8/KSHV-related diseases in posttransplant patients

Riva¹,

Luppi²,

Barozzi³

et al. 2012

Blood

View full text Add to dashboard Cite

show abstract

“…The FC studies we conducted showed that CD38, CD71, and CD30 were positive in 100% of PELs. 78 Although PEL, including its solitary variant and large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, are both positive for HHV8, the latter is typically negative for CD138 and EBV, 80 which distinguishes this type of aggressive B-cell lymphoma from traditional PBL. ALK þ large B-cell lymphoma is a rare, aggressive B-cell lymphoma, which can be difficult to diagnose, and is typically negative for most of the common B-cell antigens but positive for PC markers such as CD138, VS38, EMA, and MUM1.…”

Section: Aggressive B-cell Lymphoma With Immunophenotypic or Morpholomentioning

confidence: 99%

“…76 The antigens CD38, CD138, and MUM1 are positive in all cases of plasmablastic PCM, PBL, and PEL. [77][78][79] However, plasmablastic PCM and PBL cannot be separated from each other based on an IHC panel that includes CD45, CD79a, CD56, and PAX5, according to Vega et al 77 ; however, EBV was found to be 100% positive in 9 cases of PBL but negative in 7 cases of plasmablastic PCM. In our opinion, CD19 should be included in this panel, which may aid in distinguishing these 2 lymphomas.…”

Section: Aggressive B-cell Lymphoma With Immunophenotypic or Morpholomentioning

confidence: 99%

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Wang

Zu²

2017

Archives of Pathology &Amp; Laboratory Medicine

Self Cite

View full text Add to dashboard Cite

Context.-Different types of mature B-cell lymphomas, including plasma cell neoplasms, exhibit distinct immunohistochemical profiles, which enable them to be correctly diagnosed. However, except for rare examples of lymphoma-specific immunohistochemistry, such as cyclin D1 in mantle cell lymphoma and annexin A1 in hairy cell leukemia, immunohistochemical profiles of mature B-cell lymphomas overlap and lack specificity.Objectives.-To systemically review immunohistochemical features associated with commonly encountered mature B-cell lymphomas based on the presence or absence of CD5 and CD10; to review the immunophenotypic profile of plasma cells derived from plasma cell myelomas and B-cell lymphomas; and to review a group of rare, aggressive B-cell lymphomas with antigen expression features of plasma cells.Data Sources.-Published and PubMed-indexed English literature was reviewed.Conclusions.-Although the presence or absence of CD5 and CD10 expression should be included in the initial immunohistochemistry screening panel for mature B-cell lymphomas, appropriate and judicial use of other B-cell antigens is necessary to ensure correct diagnoses. Furthermore, although the status of CD5 and CD10 expression is associated with certain prototypes of B-cell lymphomas, their expression is not specific. Plasma cells from plasma cell neoplasias and B-cell lymphomas exhibit overlapping but relatively distinct immunophenotypes; thus, a panel of immunohistochemical markers (CD19, CD45, CD56, and CD117) can be employed for their proper identification. Lastly, CD138 staining results are almost always positive in a group of aggressive B-cell lymphomas with plasmablastic features, including plasmablastic plasma cell myeloma, plasmablastic lymphoma, and ALK-1 þ large B-cell lymphoma.

show abstract

“…They are B-lineage neoplasms but often lack expression of B-lineage markers. Occasional cases may aberrantly express a T-lineage marker (16), such as in our case report. They frequently express cell surface activation markers such as CD30, CD38, CD71, and EMA.…”

Section: Discussionmentioning

confidence: 79%

“…Occasional Reed-Sternberg-like cells may be seen. Phenotypically, PEL shows evidence of hematolymphoid derivation (i.e., greater than 90% of cases express the leukocyte common antigen CD45) (16); but may otherwise have a relatively indeterminate immunophenotype. They are B-lineage neoplasms but often lack expression of B-lineage markers.…”

Section: Discussionmentioning

confidence: 99%

Case Study Interpretation - Fort Lauderdale: Case 4

Fuda

2013

Cytometry

View full text Add to dashboard Cite

Notch1 in primary effusion lymphoma: a clinicopathological study

Cited by 26 publications

References 30 publications

How I treat HHV8/KSHV-related diseases in posttransplant patients

How I treat HHV8/KSHV-related diseases in posttransplant patients

Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry

Case Study Interpretation - Fort Lauderdale: Case 4

Contact Info

Product

Resources

About